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Complement component 5a (C5a) is a 74 amino acid glycoprotein and an important proinflammatory mediator that is cleaved 
enzymatically from its precursor, C5, on activation of the complement cascade. C5a is quickly metabolised by carboxypepti-
dases, forming the less-potent C5a desArg. C5a and C5a desArg interact with their receptors (C5aR and C5L2), which results 
in a number of effects which are essential to the immune response. C5a has a broad range of biological effects throughout the 
human body because the widespread expression of C5a receptors throughout the human organs enables C5a and C5a desArg to 
elicit a broad range of biological effects. Recently, accumulating evidence in humans and experimental animal models shows 
that the C5a-C5aR axis is involved in the development of atherosclerosis lesions. The absence or blockade of C5aRs greatly 
reduces the formation of atherosclerotic lesions or wire-injury-induced neointima formation in atherosclerosis-prone mice. Se-
rum C5a level was related to the major adverse cardiovascular events in patients with advanced atherosclerosis and those with 
drug-eluting stent implantation. Thus, the C5a-C5aR axis may be a significant pathogenic driver of arteriosclerotic vascular 
disease, making C5a-C5aR inhibition an attractive therapeutic strategy. 
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Cardiovascular disease, a worldwide leading cause of mor-
tality, is caused mainly by atherosclerosis, a chronic in-
flammatory disease of blood vessels driven by innate and 
adaptive immune responses [1,2]. As an important part of 
innate immunity, complement system has also been impli-
cated in the development of atherosclerosis [3]. Various 
complement activation products, regulatory proteins, and 
complement receptors have been detected in human and 
animal atherosclerotic lesions, particularly in vulnerable and 
ruptured plaques, and deposition of C5b-9 has been shown 
to correlate with the extent of disease [4,5]. The role of 
complement in atherogenesis was also investigated with 
complement deficient animals. C3 deficiency was found to 
increase lipid-positive lesions in the mouse aorta and alter 
the plasma lipid profile [6]. However, contrasting results 
were obtained in C5-deficient ApoE knockout (ApoE) 
mice, with the extent of atherosclerotic lesions similar to 
that in complement-competent control mice [7]. 
The complement system consists of more than 30 pro-
teins, mainly proteases, which are activated in response to 
tissue injury, invading pathogens or other foreign surfaces. 
This system could be activated by four pathways: the clas-
sical pathway, the lectin pathway, the alternative pathway 
and the extrinsic protease pathway (Figure 1). The classical 
pathway is activated by antibodies bound to antigens in 
immune complexes, and the lectin pathway is activated by 
microbial sugars such as mannose-binding lectin. The al-
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Figure 1  The four activation pathways of complement system: classical pathway, lectin pathway, alternative pathway and the extrinsic protease pathway. 
ternative pathway can be activated by foreign surfaces or by 
spontaneous hydrolysis of C3. The extrinsic protease path-
way involves direct cleavage of C3 and C5 by proteases 
such as thrombin [8].  
Protease C5-convertase, which is produced in the proce-
dure of complement activation, cleaves complement com-
ponent C5 into C5a and C5b fragments. C5a is one of the 
major biologically active components of the complement 
system and exerts its functions mainly via the canonical C5a 
receptor (C5aR, CD88) [9,10]. Recently, the C5a-C5aR axis 
has been implicated in the development of atherosclerotic 
lesions. This review gives an outline of current knowledge 
of the role of the C5a-C5aR axis in atherosclerosis and 
therapeutic strategies that may be developed to combat its 
pro-atherogenic effects. 
1  Structure and functions of C5a and C5a re-
ceptors 
C5, the precursor of C5a, is a 1676 amino acid protein 
whose gene is located at 9q33–9q34. It is mainly produced 
by liver hepatocytes, although cells such as macrophages 
can independently synthesize and secrete C5 and thus may 
be local sources of C5a generation [11]. C5a is a glycopro-
tein of 74 amino acids (≈11 kD) released from the al-
pha-chain of C5 during complement activation. C5a has 
four anti-parallel alpha helices connected by peptide loops 
and stabilized by three critical disulphide linkages. Its ago-
nist activity is derived from its C-terminal region, which 
assumes an elongated 1.5-turn helix that spans residues 
69–74 and is attached to the helical core by a four-residue 
loop. It is a potent bioactive molecule that can act on its 
high affinity binding transmembrane receptors, C5aR/CD88 
and C5L2, which are expressed by a wide variety of cell 
types throughout the human body [10,12]. Once plasma C5a 
is released from its precursor C5, plasma carboxypeptidases 
rapidly metabolize C5a by cleaving the C-terminal arginine 
to a less potent form, C5a desArg. C5a desArg has reduced 
potency as compared with C5a, which is in line with a  
reduced binding affinity for the classical C5a receptor, 
CD88 [13].  
C5a binds with similar high affinity to CD88 and C5L2. 
Both of these receptors are glycosylated, 7-transmembrane 
spanning proteins with molecular weights of about 45 kD. 
CD88 is a G-protein-coupled signaling receptor, but C5L2 
is unable to couple to G proteins because of lack of critical 
intracellular amino acid motifs. CD88 and C5L2 share 
about 35% sequence homology and are located in the same 
region of chromosome 19 (19q13.3–19q13.4) [14]. Both 
receptors are expressed on immune as well as non-immune 
cells; however, C5L2 is expressed at lower levels as com- 
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pared with CD88. CD88 activation leads to increased intra-
cellular calcium levels and activation of intracellular sig-
naling cascades accompanied by a number of functional 
responses such as recruitment and activation of inflamma-
tory cells, production of cytokines and chemokines, and 
release of granule-based enzymes [15,16]. On the other 
hand, C5L2 may act as a non-signaling decoy receptor reg-
ulating the extracellular bioavailability of C5a, thereby lim-
iting the pro-inflammatory response of C5a. However, re-
cently C5L2 was also found to facilitate C5a signaling in 
neutrophils, macrophages and fibroblasts. In addition, recent 
studies showed that C5L2 has a pro-inflammatory role in 
experimental sepsis and allergic asthma and may also con-
trol the development of Th17 cells [17].  
2  Expression of the C5a-C5aR axis in athero-
sclerosis 
Complement components have been detected in atheroscle-
rotic lesions, from the fatty streak through to complicated 
advanced plaques, but not in normal arteries [3]. C5 (the 
precursor of C5a and C5b-9/membrane attack complex) is 
expressed at both mRNA and protein levels in atheroscle-
rotic arteries [18]. C5a has also been detected by immuno-
histochemical analysis of human coronary plaques, and a 
high circulating level of C5a was found in patients with 
advanced atherosclerosis [19,20]. The canonical C5a recep-
tor, CD88, is expressed by various cell types found in hu-
man atherosclerotic plaque, including immune cells (such as 
macrophage and mast cells) and non-immune cells (smooth 
muscle cells and endothelial cells). In addition, increased 
expression of CD88 was detected in aortas in atherosclerot-
ic-prone mice, and this increase coincided with atheroscle-
rotic lesion development [21]. Although mRNA expression 
of C5L2 in aortas was lower in ApoE mice than wild-type 
mice, prominent C5L2 expression in advanced atheroscle-
rotic lesions was found in human beings and its level was 
directly correlated with local levels of proinflammatory 
cytokines [21,22] . 
3  Influence of C5a-C5aR activation on pro- 
atherogenic cells 
Although little is known about the influence of C5a on ath-
erogenesis, activation of CD88 is known to have a range of 
biological effects that may contribute to the atherogenic 
process (Figure 2). C5a is a strong chemotactic factor for 
monocytes, T lymphocytes and mast cells [23]. Endothelial 
cells showed enhanced surface and mRNA expression of 
C5aR on stimulation with lipopolysaccharide, interferon γ, 
and interleukin 6 (IL-6), concomitant with up-regulation of 
macrophage inflammatory protein 2 and monocyte chemo-
attractant protein 1 [24]. C5a may also affect the migration 
of inflammatory cells into the intima by inducing the ex-
pression of adhesion molecules such as P-selectin, E-   
selectin, intracellular adhesion molecule 1 and vascular cell 
 
 
Figure 2  The molecular mechanism of the proatherogenic role of C5a. 
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adhesion molecule 1 in endothelial or smooth muscle cells 
[2527]. In addition, C5a can directly activate inflammatory 
cells, causing the release of cytokines, expression of related 
receptors, secretion of lysosomal enzymes from macro-
phages, proliferation of T lymphocytes, and degranulation 
of mast cells [28]. Recently, C5a was found involved in 
cholesterol crystal-induced production of cytokines (in-
cluding IL-1β and tumor necrosis factor), complement re-
ceptor 3, reactive oxygen species and active caspase 1 [29]. 
4  Animal experimental evidence for the role of 
C5a-C5aR in atherosclerosis 
The role of C5a-C5aR axis in atherogenesis was investigat-
ed in atherosclerotic-prone mice. In a model of wire-   
induced endothelial denudation of the carotid artery, 
one-week treatment with C5aRA or anti-C5aR-blocking 
monoclonal antibody limited neointimal hyperplasia and 
reduced inflammatory cell content through inhibiting the 
expression of vascular cell adhesion molecule-1 [27]. 
Treating ApoE mice with a CD88 antagonist, PMX53, for 
25 weeks reduced lesion size and lipid content in plaque by 
about 40% [21]. Immunization of mice with C5aR-derived 
peptides (designated as C5aR-P1 (aa 121) and C5aR-P2 
(aa 1931)) was effective in reducing early atherosclerotic 
lesion development by inducing a specific regulatory T-cell 
response as well as blockage of monocytes differentiating 
into macrophages. Besides, the combined peptide was more 
potential than either peptide alone in reducing atheroscle-
rotic lesion formation. The molecular mechanism may be 
that vaccination with peptides promotes a major shift away 
from proinflammatory cytokines (i.e., TNF-α and IFN-γ) 
toward anti-inflammatory cytokines (IL-10 and TGF-β) [30]. 
In addition, C5a and C5a-receptor (CD88) expression was 
found to be up-regulated during vein graft disease in 
apolipoprotein E-deficient mice. C5a application accelerat-
ed vein graft lesion formation through mast cell activation, 
whereas treatment with a C5aR antagonist, PM205, resulted 
in decreased vein graft disease [31].  
5  Serum C5a level and the prognosis of athero-
sclerosis 
Complement activation occurs in atherosclerotic lesions; 
particularly, complement component C5a has potent chem-
otactic and proinflammatory effects. The relationship be-
tween plasma levels of C5a and cardiovascular risk has 
been investigated. In a study of 471 patients, serum C5a 
level was found significantly associated with acute coronary 
syndrome [32]. As well, elevated C5a level may be associ-
ated with increased cardiovascular risk (myocardial infarc-
tion, percutaneous coronary interventions, coronary artery 
bypass graft, carotid revascularization, stroke, and death) in 
patients with advanced atherosclerosis after a median fol-
low-up of 22 months [20]. C5a levels at baseline were sig-
nificantly higher in patients showing stent restenosis at fol-
low-up and significantly associated with angiographic late 
lumen loss, which is independent of other clinical and pro-
cedural risk factors [33]. A similar result was found in pa-
tients with balloon angioplasty of the superficial femoral 
artery [34]. The C5 rs17611 GG genotype was found asso-
ciated with increased C5a plasma level and represents a risk 
factor of adverse cardiovascular outcome in male patients 
with carotid atherosclerosis [35]. In patients who underwent 
combined aortic valve replacement and coronary artery by-
pass grafting, the administration of an antibody against C5 
(the precursor of C5a) was associated with decreased mor-
tality at 180-day follow-up [36]. 
6  Conclusion 
Although the precise role of the C5a-C5aR interaction in 
atherosclerosis remains the subject of continuing investiga-
tion, the papers that have emerged over the last year shows 
that the C5a-C5aR axis is an important factor in the devel-
opment of atherosclerotic lesions. Targeting the generation 
of C5a and C5b or inhibiting the two C5a receptors, there-
fore, becomes an attractive target for drug development.  
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